Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$10.8 million.

  • TriSalus Life Sciences' Consolidated Net Income fell 35064.61% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.6 million, marking a year-over-year increase of 2877.86%. This contributed to the annual value of -$30.0 million for FY2024, which is 4938.77% up from last year.
  • Per TriSalus Life Sciences' latest filing, its Consolidated Net Income stood at -$10.8 million for Q3 2025, which was down 35064.61% from -$8.3 million recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year Consolidated Net Income high stood at $2.8 million for Q1 2022, and its period low was -$35.6 million during Q4 2023.
  • Its 4-year average for Consolidated Net Income is -$9.6 million, with a median of -$8.3 million in 2025.
  • Examining YoY changes over the last 5 years, TriSalus Life Sciences' Consolidated Net Income showed a top increase of 8239.22% in 2023 and a maximum decrease of 68560.77% in 2023.
  • TriSalus Life Sciences' Consolidated Net Income (Quarter) stood at -$22.5 million in 2022, then plummeted by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then fell by 6.95% to -$10.8 million in 2025.
  • Its Consolidated Net Income stands at -$10.8 million for Q3 2025, versus -$8.3 million for Q2 2025 and -$10.4 million for Q1 2025.